YourChoice Therapeutics Board Member Presents Male Contraceptive Phase 1a Study at ACS Spring 2024

Gunda Georg, co-creator of YCT-529, presented an update on the phase 1a clinical trial of the novel hormone-free male contraceptive pill at the American Chemical Society's Spring Meeting in New Orleans, concluding on March 21, 2024. The drug, developed by San Francisco-based biotech startup YourChoice Therapeutics, began its phase 1 study in December 2023, focusing on the safety, tolerability, and pharmacological properties of YCT-529 in a group of 16 participants. The study is anticipated to be completed by mid-2024.
Dr. Georg, a distinguished professor and director at the University of Minnesota, highlighted the significance of contraceptive equity and the shared responsibility in pregnancy prevention. YCT-529 operates by inhibiting sperm production through the blocking of retinoic acid, a form of vitamin A, in the testes. Preclinical studies have demonstrated its effectiveness and complete reversibility without side effects.
Akash Bakshi, CEO of YourChoice Therapeutics, emphasized the demand for hormone-free birth control options and the potential impact of YCT-529 on reproductive equality. The company, established in 2018, is currently conducting the phase 1a trial of YCT-529 and aims to apply its therapeutic platform to develop hormone-free contraceptive products for women as well. YourChoice Therapeutics has received significant funding, including a $15M Series A round in 2022, and is collaborating with Dr. Georg and the Male Contraceptive Initiative to advance the clinical trial.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!